YN340086 PKI-166 187724-61-4

PKI-166 is a potent, selective and orally bioavailableEGFR tyrosine kinaseinhibitor, with an IC50 of 0.7nM.

YN340112 AG1557 189290-58-2

AG-1557 is a specific and ATP competitive inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase.

YN340003 PD-161570 192705-80-9

PD-161570 is a potent and ATP-competitivehuman FGF-1 receptorinhibitor with an IC50 of 39.9nM and a Ki of 42nM. PD-161570 also inhibits the PDGFR,EGFR and c-Src tyrosine kinaseswith IC50 values of 310nM, 24...

YN340041 CL-387785 194423-06-8

CL-387785 (EKI-785) is an irreversible, and selective EGFR inhibitor with IC50 of 370 pM.

YN340151 PD168393 194423-15-9

PD168393 is an irreversible EGFR inhibitor with IC50 of 0.70 nM, irreversibly alkylate Cys-773 inactive against insulin, PDGFR, FGFR and PKC.

YN340039 Falnidamol 196612-93-8

Falnidamol (BIBX 1382) is an orally active, selectiveEGFR tyrosine kinaseinhibitor with an IC50 of 3nM. Falnidamol displays > 1000-fold lower potency against ErbB2 (IC50=3.4μM) and a range of other related tyrosine kina...

YN340290 Cetuximab 205923-56-4

Cetuximab (C225) is a monoclonal antibody that inhibits epidermal growth factor receptor (EGFR), with aKdof 0.201nM for soluble EGFR by SPR. Cetuximab has potent antitumor activity.

YN340150 WHI-P154 211555-04-3

WHI-P154 is a potent JAK3 inhibitor with IC50 of 1.8 μM, no activity against JAK1 or JAK2, also inhibits EGFR, Src, Abl, VEGFR and MAPK, prevents Stat3, but not Stat5 phosphorylation.

YN340183 WHI-P180 211555-08-7

WHI-P180 is a multi-kinase inhibitor with IC50 values of 4.5 and 66 nM for the human proto-oncogene RET and kinase insert domain receptor (KDR) , respectively.

YN340245 Lapatinib 231277-92-2

Lapatinib, used in the form of Lapatinib Ditosylate, is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively.

YN340092 Erlotinib mesylate 248594-19-6

Erlotinib mesylate (CP-358774 mesylate) inhibits purifiedEGFRkinase with an IC50 of 2nM.

YN340230 Pelitinib 257933-82-7

Pelitinib (EKB-569) is a potent irreversible EGFR inhibitor with IC50 of 38.5 nM. Phase2.

YN340047 Canertinib 267243-28-7

Canertinib (CI-1033) is a pan-ErbB inhibitor for EGFR and ErbB2 with IC50 of 1.5 nM and 9.0 nM, no activity to PDGFR, FGFR, InsR, PKC, or CDK1/2/4. Phase 3.

YN340048 Canertinib dihydrochloride 289499-45-2

Canertinib (CI-1033, PD-183805, compound 18) dihydrochloride is a potent and irreversible inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase. Canertinib dihydrochloride inhibits cellular EGFR an...

YN340134 Mubritinib 366017-09-6

Mubritinib (TAK-165) is a potent inhibitor of HER2/ErbB2 with IC50 of 6 nM in BT-474 cell no activity to EGFR, FGFR, PDGFR, JAK1, Src and Blk in BT-474 cell line. Phase 1.

YN340292 Pertuzumab 380610-27-5

Pertuzumab, a humanized monoclonal antibody, is aHER2dimerization inhibitor for the treatment of metastatic HER2-positive breast cancer.

YN340159 CP-724714 383432-38-0

CP-724714 is a potent, selective and orally activeErbB2 (HER2)tyrosine kinase inhibitor, with an IC50 of 10nM. CP-724714 displays a marked selectivity against EGFR kinase (IC50=6400nM). CP-724714 potently inhibits Er...

YN340246 Lapatinib ditosylate 388082-77-7

Lapatinib (GW-572016) Ditosylate is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively.

YN340293 ZD-4190 413599-62-9

ZD-4190 is a submicromolar inhibitor of VEGF RTK activity in vitro with IC50 values of 29 ± 4 nM and 708 ± 63 nM for KDR and Flt-1, respectively.

YN340046 AV-412 free base 451492-95-8

AV-412 free base (MP-412 free base) is an EGFRinhibitor with IC50s of 0.75, 0.5, 0.79, 2.3, 19nM for EGFR, EGFRL858R, EGFRT790M, EGFRL858R/T790M and ErbB2, respectively.